Homovanillyl alcohol (HVA), HVA isomer, methods of making compositions comprising such compounds, and methods using such compounds

Compositions enriched with homovanillyl alcohol and its isomer, produced through specific enzymatic and probiotic pathways, address the limitations of current bone health treatments by enhancing bone formation and reducing bone resorption, offering improved efficacy and safety for conditions like osteoporosis and osteoarthritis.

WO2019092069A2 Publication Date: 2019-05-16SOCIETE DES PRODUITS NESTLE SA
9 Cites 26 Cited by

Patent Information

Application Number
PCT/EP2018/080550
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-08-29
Filing Date
2018-11-08
Publication Date
2019-05-16

AI Technical Summary

Technical Problem

Current treatments for stimulating bone formation and inhibiting bone resorption have limited success, and there is no effective cure for osteoarthritis, with existing therapies often associated with side effects such as gastrointestinal or cardiovascular risks.

Method used

The development of compositions containing homovanillyl alcohol (HVA) and its isomer 3-hydroxy-4-methoxyphenethanol, which are more effective than hydroxytyrosol in promoting bone health, involving pathways that include the use of probiotics, enzymes with glycosidase and esterase activity, and methyltransferase to enhance olive polyphenols, leading to increased production of HVA and its isomer.

Benefits of technology

These compositions effectively stimulate bone formation, inhibit bone resorption, and improve cartilage health, reducing the incidence of bone and joint disorders, including osteoporosis and osteoarthritis, with reduced side effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A composition contains at least one of homovanillyl alcohol (HVA) or its previously unidentified isomer (isoHVA). Additionally or alternatively, the composition contains a precursor of HVA and / or isoHVA (e.g., hydroxytyrosol, oleuropein aglycone, oleuropein, demethyloleuropein, oleuroside, verbascoside or mixtures thereof) and also contains at least one probiotic and / or at least one enzyme which convert the precursor to HVA and / or isoHVA in vivo (and / or an intermediate compound then subjected to methylation in vivo to form HVA and / or isoHVA). The composition can be administered to an individual to treat or reduce incidence of impaired mobility in an older adult; stimulate bone formation and / or inhibit bone resorption; treat or reduce incidence of synovitis in an individual in need or at risk thereof; treat or reduce incidence of articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or treat or reduce incidence of cartilage breakdown.
Need to check novelty before this filing date? Find Prior Art